TY - JOUR
T1 - Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
AU - Miyazaki, Yasushi
AU - Tuechler, Heinz
AU - Sanz, Guillermo
AU - Schanz, Julie
AU - Garcia-Manero, Guillermo
AU - Solé, Francesc
AU - Bennett, John M.
AU - Bowen, David
AU - Fenaux, Pierre
AU - Dreyfus, Francois
AU - Kantarjian, Hagop
AU - Kuendgen, Andrea
AU - Malcovati, Luca
AU - Cazzola, Mario
AU - Cermak, Jaroslav
AU - Fonatsch, Christa
AU - le Beau, Michelle M.
AU - Slovak, Marilyn L.
AU - Santini, Valeria
AU - Lübbert, Michael
AU - Maciejewski, Jaroslaw
AU - Machherndl-Spandl, Sigrid
AU - Magalhaes, Silvia M. M.
AU - Pfeilstöcker, Michael
AU - Sekeres, Mikkael A.
AU - Sperr, Wolfgang R.
AU - Stauder, Reinhard
AU - Tauro, Sudhir
AU - Valent, Peter
AU - Vallespi, Teresa
AU - van de Loosdrecht, Arjan A.
AU - Germing, Ulrich
AU - Haase, Detlef
AU - Greenberg, Peter L.
PY - 2018
Y1 - 2018
N2 - Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous studies have suggested such differences between Asian and European/USA countries. In this study, to elucidate potential differences in primary untreated MDS between Japanese (JPN) and Caucasians (CAUC), we analyzed the data from a large international database collected by the International Working Group for Prognosis of MDS (300 and 5838 patients, respectively). JPN MDS were significantly younger with more severe cytopenias, and cytogenetic differences: less del(5q) and more +1/+1q, -1/del(1p), der(1;7), -9/del(9q), del(16q), and del(20q). Although differences in time to acute myeloid leukemia transformation did not occur, a significantly better survival in JPN was demonstrated, even after the adjustment for age and FAB subtypes, especially in lower, but not in higher prognostic risk categories. Certain clinical factors (cytopenias, blast percentage, cytogenetic risk) had different impact on survival and time to transformation to leukemia between the two groups. Although possible confounding events (e.g., environment, diet, and access to care) could not be excluded, our results indicated the existence of clinically relevant ethnic differences regarding survival in MDS between JPN and CAUC patients. The good performance of the IPSS-R in both CAUC and JP patients underlines that its common risk model is adequate for CAUC and JP.
AB - Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous studies have suggested such differences between Asian and European/USA countries. In this study, to elucidate potential differences in primary untreated MDS between Japanese (JPN) and Caucasians (CAUC), we analyzed the data from a large international database collected by the International Working Group for Prognosis of MDS (300 and 5838 patients, respectively). JPN MDS were significantly younger with more severe cytopenias, and cytogenetic differences: less del(5q) and more +1/+1q, -1/del(1p), der(1;7), -9/del(9q), del(16q), and del(20q). Although differences in time to acute myeloid leukemia transformation did not occur, a significantly better survival in JPN was demonstrated, even after the adjustment for age and FAB subtypes, especially in lower, but not in higher prognostic risk categories. Certain clinical factors (cytopenias, blast percentage, cytogenetic risk) had different impact on survival and time to transformation to leukemia between the two groups. Although possible confounding events (e.g., environment, diet, and access to care) could not be excluded, our results indicated the existence of clinically relevant ethnic differences regarding survival in MDS between JPN and CAUC patients. The good performance of the IPSS-R in both CAUC and JP patients underlines that its common risk model is adequate for CAUC and JP.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85053182855&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30219650
U2 - https://doi.org/10.1016/j.leukres.2018.08.022
DO - https://doi.org/10.1016/j.leukres.2018.08.022
M3 - Article
C2 - 30219650
SN - 0145-2126
VL - 73
SP - 51
EP - 57
JO - Leukemia research
JF - Leukemia research
ER -